Broncho-munal®; Placebo
Проводит Сандоз АГ
Страница компанииA Randomized Double-blind Placebo-controlled Comparative Multicenter Study of the Efficacy and Safety of Broncho-munal®, Capsules, 7 mg (Sandoz dd, Slovenia) in the Treatment of Patients With Acute Uncomplicated Respiratory Tract Infections
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT05588804/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–60 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 556 чел. во всех странах исследования.
- Плановая дата окончания (12.2022) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 11 · невключение: 32
Критерии включения
- Patient signing and dating of the Patient Information Sheet Informed Consent Form.
- Men and women between the ages of 18 and 60 inclusive at the time of signing the Patient Information Sheet Informed Consent Form.
- Symptoms of acute uncomplicated respiratory tract infection of mild to moderate severity:
- The presence of two or more symptoms of moderate severity or three or more symptoms of mild severity according to the WURSS-21 questionnaire
- The presence of two or more symptoms of moderate severity or three or more symptoms of mild severity according to the CCQ questionnaire
- Body temperature ≥ 37.50 ° C and ≤ 40.0 ° C since the onset of the disease.
- Duration of disease symptoms less than 36 hours prior to randomization.
- The patient's consent to use reliable contraceptive methods throughout the study and for 3 weeks after its completion. The following may take part in the study:
- women who have a negative pregnancy test and are using the following contraception: barrier method (condom or occlusion cap (diaphragm or cervical / vaulted cap)) or dual barrier method of contraception (condom or occlusive cap (diaphragm or cervical / sperm cap (cid) plus foam / gel / film / cream / suppository)). The study may also include women who are unable to bear children.
- (history: hysterectomy, tubal ligation, infertility, menopause for more than 1 year).
- Or men with safe reproductive function using barrier contraception, as well as men with infertility or previous vasectomy history.
Критерии невключения
- Aggravated history of allergies, including food allergies
- Intolerance to drugs, incl. hypersensitivity or idiosyncrasy to Broncho-munal® or its excipients and to any other product from the concomitant / standard treatment
- A positive result of the analysis performed by the PCR method for the presence of SARS-CoV-2 RNA at the screening stage.
- Positive result of the analysis performed by Rapid Influenza Diagnostic Test for the presence of the influenza virus at the screening stage.
- Clinically confirmed of the presence of a new coronavirus infection COVID-19 in accordance with the regulatory acts of the Ministry of Health of the Russian Federation for the prevention, diagnosis and treatment of a new coronavirus infection (COVID-19), (the version is current at the time of inclusion of patients).
- Any vaccination less than 30 days before screening.
- The presence of any symptom of a severe course of the disease (fever of 40 ° C and higher, pulse - more than 120 beats / min, SBP - less than 90 mm Hg, muffled heart sounds, NPV - more than 28 per minute, the presence of complications, impairment of consciousness, seizures).
- Other infectious diseases less than 14 days before the screening visit, including those requiring local and / or systemic antibiotic therapy (cystitis, pyelonephritis, endocarditis, etc.)
- Chronic lung diseases (such as cystic fibrosis, pulmonary emphysema, tracheobchonchial dyskinesia, chronic obstructive pulmonary disease (COPD), bronchiectasis, etc.) in the acute stage.
- Bronchial asthma and chronic bronchitis in history.
- Pulmonary tuberculosis (active or inactive form).
- The use of drugs with immunomodulatory (including Broncho-munal) and / or immunostimulating and / or immunosuppressive effects, less than 1 month before screening.
- The need to use drugs from the list of prohibited therapy.
- Peptic ulcer of the stomach and duodenum or other erosive and ulcerative lesions of the gastrointestinal tract in the acute stage.
- Syndrome of malabsorption or other clinically significant disease of the gastrointestinal tract (uncorrected vomiting, diarrhea, ulcerative colitis, and others).
- Deficiency of the enzyme glucose-6-phosphate dehydrogenase.
- Dehydration, hypovolemia, anorexia, bulimia and cachexia (insufficient supply of glutathione in the liver) according to the anamnesis at the time of screening.
- Autoimmune diseases, according to anamnesis (systemic lupus erythematosus, rheumatoid arthritis, etc.).
- Uncontrolled diabetes mellitus.
- Syndrome of renal or hepatic insufficiency, confirmed by physical examination data.
- Positive result of any of the following tests: blood test for Hep. B, Hep.C, HIV and/or syphillis.
- Chronic heart failure III - IV functional class according to the functional classification of the New York Heart Association (NYHA), including unstable progressive angina pectoris IV functional class, uncontrolled arterial hypertension, severe arterial hypotension.
- A history of malignant neoplasms.
- Alcohol or drug addiction, history of mental illness.
- Smoking more than 20 cigarettes a day.
- Severe, decompensated or unstable somatic diseases (any diseases or conditions that threaten the patient's life or worsen the patient's prognosis, as well as make it impossible for him to participate in a clinical trial).
- Major surgery, 3 months before screening (associated with a risk to the patient's life).
- Patient's unwillingness or inability to comply with Protocol procedures (in the opinion of the investigator).
- Taking other medications that, in the Investigator's opinion, may affect the course and results of the clinical trial.
- Pregnancy or breastfeeding period.
- Participation in other clinical trials at the screening visit or for 30 days before the screening visit.
- Other conditions that, in the Investigator's opinion prevent the patient from being included in the research.
Источник: ClinicalTrials.gov, NCT05588804 · запись обновлена в реестре 4 августа 2023.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 12
- AUC value of the change in the symptom severity according to the WURSS-21 questionnaire — by 3, 5, 7 and 10 days after the start of therapy
Цель исследования
The study will evaluate the efficacy and safety of Broncho-munal®, capsules, 7 mg (Sandoz dd, Slovenia) versus Placebo in the treatment of patients with acute uncomplicated respiratory tract infections.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05588804 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.